Overview of U.S. Patent 5,612,367
U.S. Patent 5,612,367 was granted on March 18, 1997, to Millennium Pharmaceuticals Inc. It covers methods related to the use of antisense oligonucleotides targeting the Bcl-2 gene, particularly for therapeutic purposes. The patent claims detail specific sequences, methods of inhibition, and target indications, primarily in oncology and other diseases where Bcl-2 overexpression occurs.
What Is the Scope of Patent 5,612,367?
Main Focus of the Claims
The patent claims a method involving antisense oligonucleotides complementary to specific sequences of the Bcl-2 mRNA. The primary claims specify:
- Sequence-specific antisense oligonucleotides targeting the initiation codon or other regions of Bcl-2 mRNA.
- Method of inhibiting Bcl-2 gene expression in mammalian cells through administration of these oligonucleotides.
- Therapeutic applications, especially in treating cancers where Bcl-2 is overexpressed, such as lymphoma and leukemia.
Claim Structure
The claims are structured into independent and dependent claims:
- Independent claims focus on the antisense oligonucleotides themselves—defined by sequences, length, and chemical modifications.
- Dependent claims specify particular sequence embodiments, chemical modifications (e.g., phosphorothioates), doses, and administration methods.
Key Claim Details
- Sequence Range: Claims encompass oligonucleotides ranging from 8 to 20 nucleotides, tailored to hybridize with target Bcl-2 mRNA regions.
- Chemical Modifications: Includes phosphorothioate backbones, 2'-methoxy, 2'-O-methyl modifications, and others enhancing stability and binding affinity.
- Target Regions: Primarily focus on the translation initiation site of Bcl-2 mRNA, but also include other regions to disrupt translation.
- Methodological Scope: Covers administering antisense oligonucleotides via various routes—parenteral, intravenous, localized.
Patent Landscape Around 5,612,367
Patent Family and Related Patents
The patent family extends to jurisdictions including Europe, Japan, and Canada, with similar claims. These counterparts generally cover:
- Specific Bcl-2 antisense oligonucleotides
- Use of modifications to improve stability and efficacy
- Therapeutic indications in cancer and autoimmune diseases
Key Competitors and Follow-On Patents
Since the initial grant, multiple patents have been filed by other entities to expand the scope:
- Proscriptive modifications: Patents claiming newer chemical modifications for antisense stability
- Alternative target sequences: Patents targeting different regions or other Bcl-2 family genes
- Delivery technologies: Patents covering nanoparticle or liposomal delivery systems for antisense oligos
Legal Status and Litigation
As of now, the patent is maintained and does not feature significant litigation, but its claims are narrow compared to the broader antisense landscape. Several later patents have challenged its scope, especially regarding the novelty of specific sequences.
Expiration and Relevance
The patent is set to expire in March 2014, considering the 20-year term from the filing date (April 23, 1994). Post-expiry, the protected methods and sequences fall into the public domain, opening avenues for generic development.
Implications for R&D and Commercialization
- The patent's expiration reduces intellectual property barriers for companies developing Bcl-2 antisense therapies.
- The scope of original claims strategically covers specific sequences and modifications, common in antisense patenting but often narrow.
- Competitors have filed numerous follow-up patents to cover broader or alternative technologies, potentially creating a landscape with overlapping claims.
Summary Data Table
| Aspect |
Details |
| Patent number |
5,612,367 |
| Filing date |
April 23, 1994 |
| Issue date |
March 18, 1997 |
| Expiration |
March 18, 2014 |
| Primary focus |
Antisense oligonucleotides targeting Bcl-2 mRNA |
| Key claims |
Sequence-specific, chemically modified oligonucleotides |
| Therapeutic areas |
Oncology (lymphoma, leukemia), autoimmune diseases |
| Related patents |
Family patents in Europe, Japan, Canada |
| Follow-on patents |
Focus on chemical modifications, delivery systems |
| Litigation status |
No significant ongoing litigation |
Key Takeaways
- U.S. Patent 5,612,367 covers specific antisense sequences targeting Bcl-2 mRNA used in cancer therapy.
- It claims methods involving administration of chemically modified oligonucleotides.
- The patent family extends globally but expired in 2014.
- The broader antisense space includes many patents covering modifications, delivery, and alternative sequences.
- The patent’s expiration opens development opportunities but competing patents potentially restrict certain uses.
Frequently Asked Questions
Q1: What is the significance of the patent's expiration?
A1: The expiration allows free use of the patented sequences and methods, enabling generic development and commercialization without licensing.
Q2: Are there ongoing patents that compete with or expand upon this patent?
A2: Yes, numerous follow-up patents cover chemical modifications, delivery methods, and other target regions, broadening the patent landscape.
Q3: How specific are the claims in Patent 5,612,367?
A3: The claims specify particular sequences (8-20 nucleotides) complementary to Bcl-2 mRNA sequences, especially around the translation initiation site, with specific chemical modifications.
Q4: Can new antisense oligonucleotides targeting Bcl-2 be developed post-expiration?
A4: Yes, provided they do not infringe on other active patents or patent families related to modifications or delivery methods.
Q5: How does the scope of this patent compare to other antisense patents?
A5: It is narrower, focusing on specific sequences and modifications. Other patents may cover broader applications, alternative sequences, or newer technological approaches.
References
[1] U.S. Patent 5,612,367, "Antisense oligonucleotides for Bcl-2 gene."
[2] World Intellectual Property Organization (WIPO), patent family extensions.
[3] Global patent databases, including Espacenet and USPTO patent status records.
[4] Scientific literature on antisense Bcl-2 therapies (e.g., Gleave and Vasiliou, "Antisense oligonucleotides targeting Bcl-2," 2000).
